DFFN - ディフュ―ジョン・ファ―マシュ―ティカルズ (Diffusion Pharmaceuticals Inc.) ディフュ―ジョン・ファ―マシュ―ティカルズ

 DFFNのチャート


 DFFNの企業情報

symbol DFFN
会社名 Diffusion Pharmaceuticals Inc (ディフュ―ジョン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Diffusion Pharmaceuticals Inc. formerly RestorGenex Corporation is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments including radiation therapy and chemotherapy. The Company''s lead product candidate transcrocetinate sodium also known as trans sodium crocetinate (TSC) is used in various cancer types in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company''s Diffusion''s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate TSC with standard-of-care radiation and chemotherapy regimens thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types with an initial focus on primary brain cancer (glioblastoma or GBM) pancreatic cancer and brain metastases.   ディフュ―ジョン・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん腫瘍の治療に使用するトランスクロセチン酸ナトリウム(TSC)の開発に従事する。がん細胞に対する放射線治療や化学療法の効果を上げるためにTSCを使用する。また、TSCはにきびなど皮膚の疾患の治療にも使用される。本社はバ―ジニア州シャ―ロッツビル。   Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
本社所在地 1317 Carlton Avenue Suite 200 Charlottesville VA 22902 USA
代表者氏名
代表者役職名
電話番号 +1 434-220-0718
設立年月日 34669
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 11人
url www.diffusionpharma.com
nasdaq_url https://www.nasdaq.com/symbol/dffn
adr_tso
EBITDA EBITDA(百万ドル) -12.11949
終値(lastsale) 0.409
時価総額(marketcap) 20683948.409
時価総額 時価総額(百万ドル) 19.72308
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 6.78838
当期純利益 当期純利益(百万ドル) -11.09095
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Diffusion Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $7M to $14.3M. Higher net loss reflects FV/Uls Adjust on Derivatives for Hedging decrease from $10.5M (income) to $0K Depreciation increase from $12K to $55K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.33.

 DFFNのテクニカル分析


 DFFNのニュース

   Diffusion Pharma’s COVID-19 Treatment Takes a Big Step Forward With the FDA  2020/05/26 14:54:54 24/7 Wall street
   Diffusion Pharma To Evaluate Drug In COVID-19-Related Respiratory Distress, Sending Stock Higher  2020/04/01 16:33:34 Benzinga
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-related complications. The Charlottesville, Virginia-based company said it has begun a cooperative research effort with University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate its Trans Sodium Crocetinate, or TSC, in patients with acute respiratory distress syndrome, or ARDS, associated with COVID-19 infection. Patients with COVID-19 infections are at risk for developing ARDS, which can lead to … Full story available on Benzinga.com
   The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data  2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
   The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout  2019/11/19 12:56:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Crispr Therapeutics AG (NASDAQ: CRSP ) DexCom, Inc. (NASDAQ: DXCM Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) )(announced a partnership with Novo Nordisk A/S (NYSE: NVO ) for developing RNAi therapies) Frequency Therapeutics Inc (NASDAQ: FREQ )(reacted to its third-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Karuna Therapeutics Inc (NASDAQ: KRTX )( announced positive results for its mid-stage schizophrenia drug) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO )(announced full results of its ORION-9 Phase 3 study of inclisiran at the American Heart Association 2019 annual meeting) Medtronic PLC (NYSE: MDT ) Neurocrine Biosciences, Inc.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   Diffusion Pharma’s COVID-19 Treatment Takes a Big Step Forward With the FDA  2020/05/26 14:54:54 24/7 Wall street
   Diffusion Pharma To Evaluate Drug In COVID-19-Related Respiratory Distress, Sending Stock Higher  2020/04/01 16:33:34 Benzinga
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-related complications. The Charlottesville, Virginia-based company said it has begun a cooperative research effort with University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate its Trans Sodium Crocetinate, or TSC, in patients with acute respiratory distress syndrome, or ARDS, associated with COVID-19 infection. Patients with COVID-19 infections are at risk for developing ARDS, which can lead to … Full story available on Benzinga.com
   The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data  2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
   The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout  2019/11/19 12:56:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Crispr Therapeutics AG (NASDAQ: CRSP ) DexCom, Inc. (NASDAQ: DXCM Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) )(announced a partnership with Novo Nordisk A/S (NYSE: NVO ) for developing RNAi therapies) Frequency Therapeutics Inc (NASDAQ: FREQ )(reacted to its third-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Karuna Therapeutics Inc (NASDAQ: KRTX )( announced positive results for its mid-stage schizophrenia drug) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO )(announced full results of its ORION-9 Phase 3 study of inclisiran at the American Heart Association 2019 annual meeting) Medtronic PLC (NYSE: MDT ) Neurocrine Biosciences, Inc.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   Diffusion Pharma’s COVID-19 Treatment Takes a Big Step Forward With the FDA  2020/05/26 14:54:54 24/7 Wall street
   Diffusion Pharma To Evaluate Drug In COVID-19-Related Respiratory Distress, Sending Stock Higher  2020/04/01 16:33:34 Benzinga
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-related complications. The Charlottesville, Virginia-based company said it has begun a cooperative research effort with University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate its Trans Sodium Crocetinate, or TSC, in patients with acute respiratory distress syndrome, or ARDS, associated with COVID-19 infection. Patients with COVID-19 infections are at risk for developing ARDS, which can lead to … Full story available on Benzinga.com
   The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data  2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
   The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout  2019/11/19 12:56:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Crispr Therapeutics AG (NASDAQ: CRSP ) DexCom, Inc. (NASDAQ: DXCM Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) )(announced a partnership with Novo Nordisk A/S (NYSE: NVO ) for developing RNAi therapies) Frequency Therapeutics Inc (NASDAQ: FREQ )(reacted to its third-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Karuna Therapeutics Inc (NASDAQ: KRTX )( announced positive results for its mid-stage schizophrenia drug) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO )(announced full results of its ORION-9 Phase 3 study of inclisiran at the American Heart Association 2019 annual meeting) Medtronic PLC (NYSE: MDT ) Neurocrine Biosciences, Inc.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ディフュ―ジョン・ファ―マシュ―ティカルズ DFFN Diffusion Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)